ABR-238901|cas:1638200-22-2|西域试剂

ABR-238901,99.25%

产品编号：Bellancom-141537| CAS NO：1638200-22-2| 分子式：C₁₁H₉BrClN₃O₄S| 分子量：394.63

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-141537		￥3800.00	杭州北京（现货）
Bellancom-141537		￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ABR-238901

产品介绍

ABR-238901 是一种口服有效的 S100A8/A9 阻滞剂，可抑制 S100A8/A9 与其受体 RAGE (晚期糖基化终产物受体) 和 TLR4(toll 样受体 4）的相互作用。ABR-238901 具有用于心肌梗塞 (MI) 研究的潜力。

生物活性

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research.

体外研究

体内研究

ABR-238901 (30 mg/kg/day; gavage; for 3 weeks) causes less angiogenesis and less IL6 and IL10 in MDSCs.
ABR-238901 (30 mg/kg/day; gavage) in combination with Bortezomib (0.6 mg/kg; sc; 2 times/week) reduces tumor load compared with treatments of either agent alone.
ABR-238901 (30 mg/kg; IP for the first 3 d and thereafter continuously p.o.; daily; for 21 days) leads to gradual deterioration of cardiac function and accelerated left ventricular remodeling in C57BL/6NRJ mice with myocardial ischemia induced by permanent coronary artery ligation. Treatment with ABR-238901 during the first 3 days post-myocardial infarction (MI) restricts the inflammatory damage and promotes a reparatory environment.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/KaLwRij mice with 5T33MMvv cells
Dosage:	30 mg/kg
Administration:	Gavage; daily; for 3 weeks
Result:	Caused less angiogenesis. Caused less IL6 and IL10 in myeloid-derived suppressor cells (MDSCs).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/KaLwRij mice with 5T33MMvv cells
Dosage:	30 mg/kg
Administration:	Gavage; daily; for 3 weeks
Result:	Caused less angiogenesis. Caused less IL6 and IL10 in myeloid-derived suppressor cells (MDSCs).

性状

Solid

溶解性数据

In Vitro:

DMSO : 33.33 mg/mL (84.46 mM; ultrasonic and warming and heat to 60°C)

H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5340 mL	12.6701 mL	25.3402 mL
5 mM	0.5068 mL	2.5340 mL	5.0680 mL
10 mM	0.2534 mL	1.2670 mL	2.5340 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.34 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液